# US Recombinant Vaccines Market > US Recombinant Vaccines Market Research Report By Product (Subunit Recombinant, Attenuated Recombinant Vaccines), By Disease (Cancer, Pneumococcal Disease, Hepatitis B, DPT) and By End-Users (Pediatrics, Adults, Veterinary) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 20.25% - **2024:** $ 75.6 Million - **2025:** $ 90.91 Million - **2035:** $ 575 Million - **Key Players:** Pfizer (US), Moderna (US), Novavax (US), Sanofi (FR), GSK (GB), Merck (US), Bavarian Nordic (DK), AstraZeneca (GB), Takeda (JP) **Report ID:** MRFR/Pharma/17384-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-recombinant-vaccines-market-18930 --- ## Market Summary ## **US Recombinant Vaccines Market Overview** As per MRFR analysis, the US Recombinant Vaccines Market Size was estimated at 60.9 (USD Million) in 2023. The US Recombinant Vaccines Market Industry is expected to grow from 78.35(USD Million) in 2024 to 473.58 (USD Million) by 2035. The US Recombinant Vaccines Market CAGR (growth rate) is expected to be around 17.769% during the forecast period (2025 - 2035). ### **Key US Recombinant Vaccines Market Trends Highlighted** The US Recombinant Vaccines Market is experiencing significant growth driven by several key market drivers. The increasing incidence of infectious diseases, coupled with rising public awareness about preventive healthcare, has led to greater acceptance and demand for vaccines. Government initiatives, such as the National Vaccine Plan, aim to enhance vaccination rates and promote research and development in the recombinant vaccine space. Moreover, advancements in biotechnology and genetic engineering are allowing for the creation of more effective and safer vaccines, making these products more appealing to healthcare providers and patients alike. Opportunities within this market are expanding, particularly in the realm of vaccine development for emerging infectious diseases and potential bioterrorism threats. The US has seen a concentrated effort from both private and public sectors to develop vaccines that can respond promptly to outbreaks. There is also a growing trend towards personalized medicine, where vaccines can be tailored to individual genetic profiles, offering a more customized approach to immunization. Recent trends in the US include increased collaboration between biotech firms and governmental agencies for vaccine development. There has been a shift towards utilizing platforms that allow rapid response to vaccine production, such as mRNA technology, which gained traction during the COVID-19 pandemic. The focus on accessibility and equitable distribution of vaccines across various demographics in the US is also becoming a priority, driven by the recognition of health disparities. Overall, the US Recombinant Vaccines Market is evolving, influenced by these trends that emphasize innovation, collaboration, and public health priorities. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Recombinant Vaccines Market Drivers** ### **Rising Demand for Preventive Healthcare** The US [Recombinant Vaccines](../../../reports/recombinant-vaccines-market-6130) Market Industry is witnessing increased attention towards preventive healthcare due to the growing public awareness about vaccination benefits. According to the Centers for Disease Control and Prevention, vaccination rates in the United States have seen improvements with influenza vaccination coverage reaching approximately 50% of the population in recent years. This trend is significantly driven by the rise in communicable diseases and the desire to prevent outbreaks. Major organizations such as the American Academy of Pediatrics and the National Foundation for Infectious Diseases are actively promoting vaccination campaigns, which supports the market's growth as more individuals seek out recombinant vaccines that are safer and show fewer side effects compared to traditional vaccines. ### **Technological Advancements in Vaccine Development** Advancements in biotechnology and genetic engineering are pivotal in shaping the US Recombinant Vaccines Market Industry. The development of novel recombinant vaccine platforms has increased production efficiency and efficacy rates. The National Institutes of Health has reported a steady increase in Research and Development (R&D) funding for vaccine development, with federal funding exceeding $1 billion annually. Furthermore, improvements in production technologies have led to a significant reduction in the time and cost associated with bringing new vaccines to market, enabling rapid responses to health emergencies. As vaccines become faster and cheaper to produce, the market is poised for significant growth. ### **Increase in Infectious Disease Outbreaks** The resurgence of infectious diseases, such as measles and pertussis, triggering public health emergencies has heightened the need for effective vaccination solutions in the US Recombinant Vaccines Market Industry. The Centers for Disease Control and Prevention reported an alarming increase in measles cases, with over 1,200 cases reported in the US in 2019, the highest number since 1992. Such outbreaks underline the urgency for innovative vaccines that can mitigate these risks. This growing concern among health authorities and the public drives demand for recombinant vaccines, leading to investments and collaborations among pharmaceutical companies and public health agencies to develop effective vaccination strategies. ## **US Recombinant Vaccines Market Segment Insights** ### **Recombinant Vaccines Market Product Insights** The US Recombinant Vaccines Market reflects significant advancement in biotechnology, with a robust focus on the Product segment, which encompasses various innovative solutions such as Subunit Recombinant and Attenuated Recombinant Vaccines. Within this realm, Subunit Recombinant Vaccines stand out for their ability to provoke a strong immune response through the use of purified protein subunits, making them particularly suitable for addressing complex infectious diseases. This method minimizes the risk of adverse reactions commonly associated with traditional vaccines, thereby gaining preference among healthcare providers and patients alike. Meanwhile, Attenuated Recombinant Vaccines are noteworthy as they utilize live organisms that have been weakened to elicit immune responses without causing disease. This particular approach holds a significant share in the market due to its effectiveness in producing lasting immunity, thus appealing to various immunization programs aimed at eradicating diseases. The US government has been actively promoting the use of vaccines, responding to public health challenges by investing in Research and Development to enhance these products, aiming to ensure the population remains resilient against emerging pathogens. Market trends reveal a growing awareness among consumers regarding vaccine safety and efficacy, contributing to the uptick in demand for recombinant vaccines. Furthermore, ongoing collaborations among biopharmaceutical companies and academic institutions are driving innovation in this space, paving the way for the development of next-generation vaccines that address unmet medical needs. However, challenges remain, such as regulatory hurdles and public perception issues related to vaccines that require strategic engagement from stakeholders across the health sector. As the industry forges ahead, opportunities for growth exist via partnerships and investments in technology that can expedite vaccine development and improve distribution efficiency across the United States. These elements together create a dynamic landscape for the Product segment within the US Recombinant Vaccines Market, highlighting the importance of continuous evolution in response to both market demands and global health priorities. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Recombinant Vaccines Market Disease Insights** The Disease segment of the US Recombinant Vaccines Market remains a critical focus area, reflecting the ongoing need for effective immunization solutions against various health threats. Among the prominent categories within this segment, Cancer vaccines are gaining significant attention due to the rising incidence of cancer in the United States, making them crucial for preventive healthcare strategies. Meanwhile, Pneumococcal Disease vaccines hold a vital role in reducing morbidity and mortality associated with pneumonia, particularly in vulnerable populations such as children and the elderly. The Hepatitis B vaccine remains a cornerstone in the fight against viral hepatitis, which poses substantial public health challenges. Additionally, the DPT (Diphtheria, Pertussis, and Tetanus) vaccines continue to be essential for maintaining herd immunity and preventing outbreaks of these diseases. The US government’s initiatives toward vaccination drive and the constant advancements in recombinant technologies are further driving the growth and significance of these vaccines, reinforcing the importance of the Disease segment in public health. Capitalizing on these trends presents opportunities for innovation and improved health outcomes across the nation. ### **Recombinant Vaccines Market End-Users Insights** The US Recombinant Vaccines Market exhibits significant insights across its End-Users segment, primarily focusing on Pediatrics, Adults, and Veterinary applications. The Pediatrics segment plays a crucial role in safeguarding children from contagious diseases, as effective vaccination strategies continue to evolve through advancements in recombinant technology. Adults are also increasingly recognized as a vital demographic, particularly as vaccine recommendations expand to encompass various age groups and health concerns. This shift underscores a growing emphasis on preventative healthcare, driven by rising awareness and the need for immunizations in combating diseases. The Veterinary segment is gaining traction as health priorities shift towards animal welfare and public safety, especially in zoonotic disease prevention, which further integrates veterinary health into the broader healthcare landscape. Various factors, including increased government support and funding for vaccine development, align with the broader trend of prioritizing health security and disease management across these subcategories. Overall, the US Recombinant Vaccines Market shows promising opportunities for continued growth and innovation within these essential End-Users. ## **US Recombinant Vaccines Market Key Players and Competitive Insights** The US Recombinant Vaccines Market is a rapidly evolving sector that leverages advanced biotechnology for the development of vaccines designed to trigger strong immune responses against various infectious diseases. As public health continues to pivot towards innovative strategies for disease prevention, the competitive landscape within this market is becoming increasingly complex. Companies operating in this space are focusing on research and development to create more effective vaccines with improved safety profiles and the capability to address emerging health threats. With advancements in recombinant DNA technology, key players are investing in partnerships and collaborations to enhance their product pipelines and gain a competitive edge. ViroClinics Xplore stands out in the US Recombinant Vaccines Market with its robust research foundations and a focus on developing customized vaccine solutions. The company has established a solid presence in the region, driven by its expertise in advanced biotechnology and vaccine research. ViroClinics Xplore is recognized for its strengths in innovative platform technologies, enabling efficient vaccine development processes against endemic and pandemic threats. The firm's commitment to quality and regulatory compliance positions it favorably in this competitive market, appealing to various stakeholders, including public health organizations and biopharmaceutical companies looking for reliable partners in vaccine development. Seqirus has made significant strides in the US Recombinant Vaccines Market, predominantly recognized for its comprehensive portfolio of influenza vaccines and other preventive solutions. The company's strengths lie in its strong market presence, innovative approaches to vaccine manufacturing, and a focus on providing high-quality immunization products. Seqirus is notable for its leadership in developing recombinant influenza vaccines that meet the demands of a diverse population. The firm has also pursued strategic mergers and acquisitions that bolster its capabilities and product offerings, enhancing its competitive position in the US. Its commitment to research and development, combined with a strategic approach to understanding market needs, empowers Seqirus to remain a key player in the recombinant vaccines landscape, catering to the public's health needs amid evolving challenges. ### **Key Companies in the US Recombinant Vaccines Market Include** ## **US Recombinant Vaccines Market Industry Developments** Recent developments in the US Recombinant Vaccines Market have highlighted significant activities among key players. In September 2023, Merck announced advancements in their recombinant vaccine pipelines aimed at enhancing global health responses, particularly in infectious disease management. Meanwhile, Moderna has reported substantial growth in their market valuation due to the successful launch of their new mRNA-based recombinant vaccines, contributing to their prominence in combating viral outbreaks. Pfizer continues to expand its recombinant vaccine portfolio with innovations focusing on personalized medicine, which has attracted considerable investments. Additionally, Inovio Pharmaceuticals has secured partnerships to further their Research and Development efforts in the recombinant domain, aiming to expedite vaccine availability. Notably, in October 2022, GlaxoSmithKline embarked on a strategic acquisition of a biotechnology firm, which strengthened their recombinant vaccine capabilities. This trend of mergers and acquisitions underscores the escalating competition and strategic collaborations within the market. The cumulative growth of companies like Johnson and Johnson and Bavarian Nordic also reflects the increasing investments and innovations tailored towards enhancing vaccine efficacy and distribution across the United States. Overall, these ongoing developments underscore a dynamic landscape in the US recombinant vaccines sector. ## **US Recombinant Vaccines Market Segmentation Insights** ### **Recombinant Vaccines Market Product Outlook** ### **Recombinant Vaccines Market Disease Outlook** ### **Recombinant Vaccines Market End-Users Outlook** ## Market Drivers ### Government Initiatives and Funding Government initiatives and funding play a crucial role in the growth of the recombinant vaccines market. In the US, federal and state governments are increasingly investing in vaccine research and development to combat infectious diseases. For example, the National Institutes of Health (NIH) allocates substantial funding for vaccine-related research, which supports the advancement of recombinant technologies. This financial backing is essential for fostering innovation and ensuring that the recombinant vaccines market remains competitive. Furthermore, public-private partnerships are emerging, facilitating collaboration between government entities and private companies. Such initiatives are likely to enhance the development pipeline of recombinant vaccines, ultimately benefiting public health. ### Innovations in Vaccine Development Innovative technologies in vaccine development are significantly impacting the recombinant vaccines market. Advances in genetic engineering and biotechnology have enabled the creation of more effective and safer vaccines. For instance, the use of recombinant DNA technology allows for the production of vaccines that can elicit stronger immune responses. The recombinant vaccines market is projected to grow at a CAGR of 8.5% from 2025 to 2030, driven by these innovations. Additionally, the ability to rapidly develop vaccines in response to emerging infectious diseases enhances the attractiveness of recombinant vaccines. This innovation not only addresses public health needs but also positions the recombinant vaccines market as a leader in the biopharmaceutical sector. ### Rising Demand for Preventive Healthcare The increasing emphasis on preventive healthcare is driving the recombinant vaccines market. As healthcare systems shift focus from treatment to prevention, the demand for vaccines that can effectively prevent diseases is surging. This trend is particularly evident in the US, where healthcare expenditures are projected to reach $4.3 trillion by 2025. The recombinant vaccines market is poised to benefit from this shift, as these vaccines offer enhanced efficacy and safety profiles. Moreover, the growing awareness of vaccine-preventable diseases among the population is likely to further stimulate demand. As a result, healthcare providers are increasingly incorporating recombinant vaccines into their immunization programs, thereby expanding their market presence. ### Growing Investment in Biopharmaceuticals The increasing investment in biopharmaceuticals is positively influencing the recombinant vaccines market. As the biopharmaceutical sector expands, there is a corresponding rise in funding for vaccine development, particularly recombinant vaccines. The US biopharmaceutical market is expected to reach $500 billion by 2025, with a significant portion allocated to vaccine research. This investment is crucial for advancing technologies that enhance vaccine efficacy and safety. Additionally, the recombinant vaccines market stands to benefit from collaborations between biopharmaceutical companies and research institutions, fostering innovation and accelerating the development of new vaccines. This trend indicates a robust future for the recombinant vaccines market as it aligns with the broader growth of the biopharmaceutical industry. ### Increasing Incidence of Infectious Diseases The rising incidence of infectious diseases is a significant driver for the recombinant vaccines market. With the emergence of new pathogens and the resurgence of previously controlled diseases, there is an urgent need for effective vaccination strategies. The Centers for Disease Control and Prevention (CDC) reports that vaccine-preventable diseases continue to pose a threat to public health in the US. This situation creates a favorable environment for the recombinant vaccines market, as these vaccines can be tailored to target specific pathogens. The urgency to develop vaccines against diseases such as influenza, Zika, and others is likely to propel market growth, as healthcare providers seek effective solutions to protect populations. ## Future Outlook The [Recombinant Vaccines Market](https://www.marketresearchfuture.com/reports/recombinant-vaccines-market-6130) is projected to grow at a 20.25% CAGR from 2025 to 2035, driven by technological advancements, increasing disease prevalence, and rising healthcare investments. **New opportunities:** - Development of personalized recombinant vaccines for niche markets. Expansion of partnerships with biotech firms for innovative product pipelines. Investment in automated manufacturing technologies to enhance production efficiency. By 2035, the recombinant vaccines market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Subunit (Largest) vs. Vector (Fastest-Growing) In the US recombinant vaccines market, subunit recombinant vaccines currently hold the largest market share, primarily due to their safety and efficacy profiles. They account for a significant portion of the overall vaccine landscape, appealing to healthcare providers and patients alike. In contrast, vector recombinant vaccines are gaining traction among researchers and pharmaceutical companies, due to their innovative approaches to immunization, which enhance the body’s immune response more effectively. Growth trends indicate a robust demand for increased vaccine options, with subunit vaccines leading the way because of their lower risk of adverse reactions. Meanwhile, vector vaccines are recognized as the fastest-growing segment, driven by advancements in biotechnology and the need for rapid responses to emerging infectious diseases, reflecting the dynamic nature of the segment. Subunit (Dominant) vs. Vector (Emerging) Subunit recombinant vaccines are highlighted as the dominant segment in the US recombinant vaccines market, recognized for their safety and ease of production. Their composition, which includes only specific proteins from the pathogen, minimizes the risk of side effects while ensuring effective immune response. On the other hand, vector recombinant vaccines, classified as emerging, utilize modified viruses or bacteria to deliver genetic material into cells, prompting a strong immune response. This innovative approach positions them as promising candidates, particularly in the face of rapidly evolving pathogens. Their adaptability and potential for fast-track development make them increasingly attractive in vaccine research and public health strategies. ### By Disease: Pneumococcal Disease (Largest) vs. Cancer (Fastest-Growing) In the US recombinant vaccines market, the distribution of market share among various diseases reveals that Pneumococcal Disease accounts for the largest segment, capturing significant attention and resources. Following closely are vaccines for Cancer and Hepatitis B, both showing substantial demand in the healthcare sector. Influenza and DPT also contribute to the overall market, but to a lesser extent, indicating growing but not dominant areas compared to Pneumococcal and Cancer vaccines. Growth trends within the disease segment are driven by increased vaccination awareness and government initiatives promoting immunization. The Cancer vaccine sector specifically is witnessing rapid advancements, attributed to ongoing research and development, enhancing efficacy and safety, thus making it the fastest-growing area. The demand for innovative vaccines against Pneumococcal Disease also remains strong, reflecting a resilient and evolving healthcare landscape. Pneumococcal Disease: Dominant vs. Cancer: Emerging Pneumococcal Disease vaccines are positioned as the dominant force within the US recombinant vaccines market, benefiting from established healthcare protocols and a robust awareness campaign concerning pneumococcal infections. These vaccines are recognized for their preventive capabilities against severe bacterial infections, leading to widespread usage in various demographic groups. On the other hand, Cancer vaccines, while emerging, are rapidly gaining traction due to increased funding and innovation in oncology. This sector focuses on personalized medicine and targeted therapies, responding to the growing incidence of cancer and the need for effective preventive measures. The interplay between these two segments illustrates a dynamic evolution in vaccine development and public health strategy. ### By End-User: Hospitals & Clinics (Largest) vs. Pediatrics (Fastest-Growing) The US recombinant vaccines market exhibits varied distribution across its end-user segments. Hospitals & Clinics hold the largest market share due to their extensive patient base and robust vaccination programs. Following closely, the Pediatrics segment is gaining traction as awareness increases around childhood immunizations with recombinant vaccines, reflecting strong demand in this sector. Growth trends indicate a significant uptick in the Pediatrics segment, driven by rising health concerns among parents and increasing government initiatives for childhood vaccination campaigns. The focus on preventive healthcare is propelling the demand for recombinant vaccines in Hospitals & Clinics. Additionally, there's a burgeoning interest in veterinary applications within Livestock and Poultry, highlighting how end-user needs are evolving in the US market. Hospitals & Clinics (Dominant) vs. Pediatrics (Emerging) Hospitals & Clinics remain the dominant end-user in the US recombinant vaccines market, characterized by large-scale operations and essential partnerships with healthcare authorities. They facilitate patient access to vaccines swiftly and effectively, thus maintaining a pivotal role in public health response strategies. Conversely, the Pediatrics segment is emerging rapidly, driven by a heightened focus on child health and preventive measures. This segment is characterized by increased research and development initiatives aimed at formulating vaccines that target specific childhood diseases. Moreover, effective awareness campaigns about the safety and efficacy of recombinant vaccines have bolstered adoption among parents, ensuring this segment's growth trajectory remains robust. ## Competitive Benchmarking The recombinant vaccines market is currently characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on addressing emerging health threats. Key players such as Pfizer (US), Moderna (US), and Novavax (US) are at the forefront, leveraging their advanced research capabilities and established market presence. Pfizer (US) has positioned itself as a leader through continuous investment in R&D, while Moderna (US) emphasizes its mRNA technology platform to develop next-generation vaccines. Novavax (US), on the other hand, is focusing on expanding its portfolio with protein-based vaccines, indicating a diverse approach among these competitors that collectively shapes the market's competitive environment.In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce lead times. This strategy appears to be particularly relevant in the context of fluctuating global supply chains. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. Their collective actions, particularly in terms of innovation and strategic collaborations, are likely to dictate market trends and consumer preferences. In October Pfizer (US) announced a partnership with a leading biotechnology firm to co-develop a novel recombinant vaccine targeting respiratory diseases. This collaboration is expected to enhance Pfizer's capabilities in vaccine development and expand its product offerings, thereby reinforcing its competitive edge. The strategic importance of this partnership lies in its potential to accelerate the development timeline and improve access to innovative solutions in the market.Similarly, in September 2025, Moderna (US) revealed plans to invest $500 million in a new manufacturing facility dedicated to recombinant vaccines. This investment underscores Moderna's commitment to scaling its production capabilities and meeting anticipated demand. The establishment of this facility is likely to enhance operational efficiency and position Moderna favorably in a competitive landscape increasingly focused on rapid response to health crises. In August Novavax (US) secured a $200 million grant from the government to support the development of its recombinant vaccine platform. This funding is pivotal for Novavax, as it not only provides financial backing but also validates the potential of its innovative approach. The strategic implications of this grant may lead to accelerated research and development timelines, positioning Novavax as a formidable competitor in the recombinant vaccines market. As of November current trends in the recombinant vaccines market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing innovation and market reach. Looking ahead, competitive differentiation is likely to evolve, shifting from traditional price-based competition to a focus on technological advancements, supply chain reliability, and innovative solutions that address public health needs. ## Recent News & Developments Recent developments in the US Recombinant Vaccines Market have highlighted significant activities among key players. In September 2023, Merck announced advancements in their recombinant vaccine pipelines aimed at enhancing global health responses, particularly in infectious disease management. Meanwhile, Moderna has reported substantial growth in their market valuation due to the successful launch of their new mRNA-based recombinant vaccines, contributing to their prominence in combating viral outbreaks. Pfizer continues to expand its recombinant vaccine portfolio with innovations focusing on personalized medicine, which has attracted considerable investments. Additionally, Inovio Pharmaceuticals has secured partnerships to further their Research and Development efforts in the recombinant domain, aiming to expedite vaccine availability. Notably, in October 2022, GlaxoSmithKline embarked on a strategic acquisition of a biotechnology firm, which strengthened their recombinant vaccine capabilities. This trend of mergers and acquisitions underscores the escalating competition and strategic collaborations within the market. The cumulative growth of companies like Johnson and Johnson and Bavarian Nordic also reflects the increasing investments and innovations tailored towards enhancing vaccine efficacy and distribution across the United States. Overall, these ongoing developments underscore a dynamic landscape in the US recombinant vaccines sector. ## Report Scope | MARKET SIZE 2024 | 75.6(USD Million) | | --- | --- | | MARKET SIZE 2025 | 90.91(USD Million) | | MARKET SIZE 2035 | 575.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 20.25% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer (US), Moderna (US), Novavax (US), Sanofi (FR), GSK (GB), Merck (US), Bavarian Nordic (DK), AstraZeneca (GB), Takeda (JP) | | Segments Covered | Type, Disease, End-User | | Key Market Opportunities | Advancements in genetic engineering enhance efficacy and safety in the recombinant vaccines market. | | Key Market Dynamics | Technological advancements drive innovation in recombinant vaccines, enhancing efficacy and expanding therapeutic applications. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the projected market valuation for the US recombinant vaccines market in 2035?** A: The projected market valuation for the US recombinant vaccines market in 2035 is $575.0 Million. **Q: What was the market valuation for the US recombinant vaccines market in 2024?** A: The overall market valuation for the US recombinant vaccines market was $75.6 Million in 2024. **Q: What is the expected CAGR for the US recombinant vaccines market during the forecast period 2025 - 2035?** A: The expected CAGR for the US recombinant vaccines market during the forecast period 2025 - 2035 is 20.25%. **Q: Which companies are considered key players in the US recombinant vaccines market?** A: Key players in the US recombinant vaccines market include Pfizer, Moderna, Novavax, Sanofi, GSK, Merck, Bavarian Nordic, AstraZeneca, and Takeda. **Q: What are the main types of recombinant vaccines in the US market?** A: The main types of recombinant vaccines in the US market include subunit recombinant vaccines, attenuated recombinant vaccines, and vector recombinant vaccines. **Q: What was the valuation of subunit recombinant vaccines in 2024?** A: The valuation of subunit recombinant vaccines in 2024 was $30.0 Million. **Q: How does the valuation of vector recombinant vaccines compare to attenuated recombinant vaccines in 2024?** A: In 2024, the valuation of vector recombinant vaccines was $20.6 Million, whereas attenuated recombinant vaccines had a valuation of $25.0 Million. **Q: What diseases are targeted by recombinant vaccines in the US market?** A: Recombinant vaccines in the US market target diseases such as pneumococcal disease, cancer, hepatitis B, influenza, DPT, and others. **Q: What is the projected valuation for the influenza segment of recombinant vaccines by 2035?** A: The projected valuation for the influenza segment of recombinant vaccines is $150.0 Million by 2035. **Q: Which end-user segments are involved in the US recombinant vaccines market?** A: End-user segments in the US recombinant vaccines market include hospitals & clinics, pediatrics, adults, veterinary, poultry, livestock, and others. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-recombinant-vaccines-market-18930*